Literature DB >> 24585905

Pericardiectomy for treatment of neoplastic constrictive pericarditis.

Fuat Buyukbayrak1, Eray Aksoy, Mehmet Dedemoglu, Kaan Kirali, Hizir Mete Alp.   

Abstract

OBJECTIVE: To share our results of a case series of 8 patients who underwent pericardiectomy for constrictive pericarditis that developed secondary to a known neoplastic disease. PATIENTS AND METHODS: The underlying neoplasia was lung cancer in 5 (62.5%) patients, malignant pleural mesothelioma in 2 (25%), and Hodgkin lymphoma in 1 (12.5%). A diagnosis of constrictive pericarditis was made primarily by echocardiography, and right heart catheterization was performed in 6 (75%) patients. Total pericardiectomy was defined as wide excision of the anterior pericardium. Follow-up information was obtained by telephone interview and the civil registry database.
RESULTS: Time from initial diagnosis of the neoplastic disease ranged from 1 to 15 years. Total pericardiectomy was performed in 6 (75%) patients. Histopathological examination revealed atypical cells in evacuated fluid and pericardial material in 6 patients. Nonspecific inflammation and fibrosis were observed in the other 2 cases. Hospital death occurred in 1 (12.5%) patient. Postoperative low cardiac output syndrome occurred in 7 (87.5%) patients. Follow-up ranged from 2.92 to 26.78 months. Mean survival was 14.82 ± 4.4 months.
CONCLUSION: Pericardial constriction may develop a long time after the initial presentation of certain neoplastic diseases, and the prognosis after pericardiectomy is poor.

Entities:  

Keywords:  Heart neoplasms; constrictive; pericardial effusion; pericardiectomy; pericarditis; treatment outcome

Mesh:

Year:  2013        PMID: 24585905     DOI: 10.1177/0218492313484317

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  1 in total

1.  Long-term outcomes of pericardiectomy for constrictive pericarditis.

Authors:  Murat Biçer; Bülent Özdemir; İris Kan; Ahmet Yüksel; Mustafa Tok; Işık Şenkaya
Journal:  J Cardiothorac Surg       Date:  2015-11-27       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.